Actueel

Nieuwe risico-informatie voor Lemtrada (relapsing-remitting MS)

U kunt deze informatie vinden op: https://www.ema.europa.eu/en/news/use-multiple-sclerosis-medicine-lemtrada-restricted-while-ema-review-ongoing .

Aanleiding voor het bericht is: There are new reports of immune-mediated conditions (caused by the body’s defence system not working properly) and problems with the heart and blood vessels with the medicine, including fatal cases.